White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions

被引:0
作者
Achinto Saha
Jill Hamilton-Reeves
John DiGiovanni
机构
[1] The University of Texas at Austin,Division of Pharmacology and Toxicology, College of Pharmacy
[2] The University of Texas at Austin,Center for Molecular Carcinogenesis and Toxicology
[3] The University of Texas at Austin,Livestrong Cancer Institutes, Dell Medical School
[4] University of Kansas Medical Center,Departments of Urology and Dietetics & Nutrition
[5] The University of Texas at Austin,Division of Pharmacology and Toxicology, College of Pharmacy
[6] Dell Pediatric Research Institute,undefined
来源
Cancer and Metastasis Reviews | 2022年 / 41卷
关键词
Prostate cancer; Chemokines; Adipose tissue; Obesity;
D O I
暂无
中图分类号
学科分类号
摘要
Obesity represents an important risk factor for prostate cancer, driving more aggressive disease, chemoresistance, and increased mortality. White adipose tissue (WAT) overgrowth in obesity is central to the mechanisms that lead to these clinical observations. Adipose stromal cells (ASCs), the progenitors to mature adipocytes and other cell types in WAT, play a vital role in driving PCa aggressiveness. ASCs produce numerous factors, especially chemokines, including the chemokine CXCL12, which is involved in driving EMT and chemoresistance in PCa. A greater understanding of the impact of WAT in obesity-induced progression of PCa and the underlying mechanisms has begun to provide opportunities for developing interventional strategies for preventing or offsetting these critical events. These include weight loss regimens, therapeutic targeting of ASCs, use of calorie restriction mimetic compounds, and combinations of compounds as well as specific receptor targeting strategies.
引用
收藏
页码:649 / 671
页数:22
相关论文
共 1289 条
[1]  
Nomura AM(2001)Body size and prostate cancer Epidemiologic Reviews 23 126-131
[2]  
Porter MP(2005)Obesity and the risk of prostate cancer Prostate 62 316-321
[3]  
Stanford JL(2004)Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results Journal of Urology 172 910-914
[4]  
Roehl KA(1999)Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1591-1597
[5]  
Han M(2011)Metabolic alterations and targeted therapies in prostate cancer The Journal of Pathology 223 283-294
[6]  
Ramos CG(2011)Body mass index, prostate cancer–specific mortality, and biochemical recurrence: A systematic review and meta-analysis Cancer Prevention Research 4 486-501
[7]  
Antenor JA(2004)Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins Journal of Urology 172 520-524
[8]  
Catalona WJ(2012)Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy Urology 80 576-584
[9]  
Pound CR(2014)Association of body mass index and prostate cancer mortality Obesity Research & Clinical Practice 8 e374-381
[10]  
Partin AW(2011)Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era Cancer Prevention Research (Philadelphia, Pa.) 4 544-551